Oruka Therapeutics, Inc. (ORKA) Return on equity 2016–2023
Oruka Therapeutics, Inc. (ORKA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-14.4%FY2023 · since FY2016: -74.1% → -14.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -14.4% | +9.4 pp |
| FY2022 | -23.8% | +14.0 pp |
| FY2021 | -37.9% | -16.9 pp |
| FY2020 | -20.9% | +51.1 pp |
| FY2019 | -72.0% | +59.5 pp |
| FY2018 | -131.5% | +48.4 pp |
| FY2017 | -180.0% | -105.9 pp |
| FY2016 | -74.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice